Obesity was not associated with an increased risk for serious infection among patients with inflammatory bowel disease treated with biologics, according to research published in Clinical and Translational Gastroenterology.

“Obesity has been associated with adverse outcomes in patients with IBD. … Obesity has also been variably associated with inferior response to therapy, particularly with biologic agents, and a lower likelihood of achieving endoscopic remission,” Siddharth Singh, MD, MS, Mayo Clinic, and colleagues wrote. “Although this negative impact of obesity on

Full Article: https://www.healio.com/news/gastroenterology/20210728/obesity-does-not-increase-risk-for-serious-infection-in-biologictreated-ibd